AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
E: ir@astrazeneca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,639.30 | 14.40 | 0.17% |
| CAC 40 | 7,788.10 | 38.69 | -0.49% |
| DAX 40 | 24,038.19 | 188.30 | -0.78% |
| Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
| FTSE 100 | 8,726.01 | 52.04 | -0.59% |
| HKSE | 23,258.31 | 123.68 | -0.53% |
| NASDAQ | 19,100.94 | 98.22 | -0.51% |
| Nikkei 225 | 38,171.81 | 449.41 | 1.19% |
| NZX 50 Index | 12,326.07 | 36.19 | -0.29% |
| S&P 500 | 5,888.55 | 32.99 | -0.56% |
| S&P/ASX 200 | 8,412.10 | 15.20 | 0.18% |
| SSE Composite Index | 3,339.93 | 0.76 | -0.02% |